Oropharyngeal Undifferentiated Carcinoma
Back to Diseases List
Associated Genetic Biomarkers
NCI Definition: A non-keratinizing carcinoma arising from the oropharynx. It is characterized by the presence of large malignant cells with vesicular nuclei, prominent nucleoli, syncytial growth pattern, and a lymphoplasmacytic infiltrate. 
There are 2 clinical trials for oropharyngeal undifferentiated carcinoma, of which 2 are open and 0 are completed or closed. Of the trials that contain oropharyngeal undifferentiated carcinoma as an inclusion criterion, 1 is early phase 1 (1 open) and 1 is phase 2 (1 open).
CDKN2A and HPV are the most frequent gene inclusion criteria for oropharyngeal undifferentiated carcinoma clinical trials .
Hb-201, nivolumab, and radiation therapy are the most common interventions in oropharyngeal undifferentiated carcinoma clinical trials.
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.